AMENDED AND RESTATED INCENTIVE COMPENSATION AGREEMENTIncentive Compensation Agreement • April 12th, 2019 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances
This Amended and Restated Incentive Compensation Agreement, dated as of April 11, 2019, is by and between ImmuCell Corporation, a Delaware corporation (the “Company”) and Bobbi Jo Brockmann (the “Executive”), and replaces and supersedes in its entirety the Incentive Compensation Agreement, dated as of March 6, 2017, between the Company and the Executive.
